Large interindividual variability has been observed in the metabolism of CYP2C19
substrates in vivo. The study aimed to evaluate sources of this variability in CYP2C19 …

Purpose Impaired antiplatelet effect of clopidogrel (CLP) can result from drug-drug
interactions and genetic polymorphisms of drug-metabolizing enzymes. The aim of the study …

Introduction CYP2C19 is a highly polymorphic gene responsible for metabolizing commonly
used drugs. CYP2C19* 2,* 3 (loss of activity alleles) and* 17 (increased activity allele) are …

Objective Information on CYP2B6 allele frequencies and detrimental genotypes in mixed
human populations is scarce. The aim of this study was to analyze the frequencies and …

Clopidogrel is an inhibitor of platelet ADP P2Y12 receptors and currently used for prevention
of stent thrombosis. Despite certain clinical benefit using this drug in patients undergoing …

CYP2C9, CYP2C19 and CYP2D6 metabolize around 40% of drugs and their genes vary
across populations. The Costa Rican population has a trihybrid ancestry and its key …

Study of the allelic variants CYP2C9*2 and CYP2C9*3 in samples of the Peruvian mestizo
population SciELO - Scientific Electronic Library Online vol.39 issue3 Genetic variability analysis …

Clopidogrel is one of the most frequently used drugs in patients to reduce cardiovascular
events. Since patients with different genetic variations respond quite differently to …

Background This study was aimed to investigate the correlation between CYP 2C19 and
ABCB 1 polymorphisms and the recurrence of ischemic cardiovascular adverse events in …

Abstract Introduction Trinidad & Tobago has the highest prevalence of cardiovascular
disease (CVD) in the Caribbean and clopidogrel is a ubiquitously used treatment. Yet, the …